This website uses cookies to enhance your browsing experience, improve site performance, and gather analytics. By selecting 'Accept,' you consent to these cookies as described in our Privacy Policy.

HomeBrowseAboutFAQs
Log In
Sign Up
Neuromyelitis Optica Spectrum Disorder

A Study of Orelabrutinib in Patients With AQP4-IgG Positive Neuromyelitis Optica Spectrum Disorder

Sponsored by Peking Union Medical College Hospital

About this trial

Last updated 3 years ago

Study ID

ICP-022-006

Status

Not yet recruiting

Type

Interventional

Phase

N/A

Placebo

No

Accepting

18-75 Years
18 to 75 Years
All
All

Not accepting

Not accepting
Healthy Volunteers

Trial Timing

Ended 2 years ago

What is this trial about?

Neuromyelitis optica spectrum disorder (NMOSD) is a chronic inflammatory demyelinating autoimmune disease of the central nervous system. NMOSD is a highly relapsing, severely disabling disease. AQP4-IgG positive NMOSD is related to a specific aquaporin 4 antibody (AQP4 IgG) produced by mature B cells. BTK is a key kinase in B cell receptor signal transduction pathway. Abnormal activation of BTK related signaling pathway can lead to autoantibody production and autoimmune diseases. Therefore, BTK can be developed as a new target for autoimmune diseases.

What are the participation requirements?

Yes

Inclusion Criteria

- 1) 18-75 years old (inclusive) at the time of signing the informed consent form

- 2)Diagnosed with AQP4-IgG positive NMOSD in accordance with 2015 IPND diagnostic criteria.

- 3)Relapse ≥ 2 within 1 year before screening, and at least 1 relapse within 6 months before screening

- 4)If the subject has stable steroids treatment (≤ 7.5mg prednisone, or equivalent dose of steroids), the treatment needs to be stable more than 1 month before starting the study drug treatment.

- 5)EDSS ≤7.5 at screening

- 6)Negative pregnancy test for female of childbearing potential at screening

- 7)Understood the study procedure and voluntarily signed written informed consent

No

Exclusion Criteria

- 1) History of serious heart, lung, liver, kidney, blood disease, etc.

- 2) Any major infection judged by the investigator requiring hospitalization and parenteral antimicrobial treatment within 1 month before screening

- 3) History of episodes of herpes zoster ≥ 2 or disseminated herpes zoster ≥ 1

- 4) History of or having any of the following medication / treatment: ① Received BTK inhibitor at any time in the past; ② B-cell targeted therapy within 12 weeks before the first dose; ③ Received biological agents within 12 weeks before the first dose; ④ Received live virus vaccine or live attenuated vaccine within 8 weeks before the first dose; ⑤ Received steroids treatment for other diseases within 6 months before screening, the dosage > 20mg / day for more than 21 days; ⑥ Used a study drug or other experimental treatment within 4 weeks before screening or 5 half-lives, or participating in any other intervention clinical trial.

- 5) During screening or baseline examination, laboratory results meet the exclusion criteria:

- Human immunodeficiency virus (HIV) positive
- Hepatitis C virus (HCV) antibody positive. (If a subject has a history of HCV infection, has completed and recorded appropriate treatment at least 1 year before screening, and the HCV RNA measured by PCR at the time of screening is negative, the subject will not be excluded from this study.)
- Hepatitis B surface antigen (HBsAg) positive and / or hepatitis B core antibody (HBcAb) positive
- Estimated glomerular filtration rate (eGFR) < 30 mL/min/1.73 m2
- ALT/AST > 2 x ULN, Total Bilirubin > 1.5 x ULN, or any other clinically significant laboratory abnormality
- Neutrophil < 1500 / mm3, platelet < 75000 / mm3, lymphocyte < 1000 / mm3 or leukocyte < 3500 / mm3.
- International standardized ratio (INR) ≥ 1.5 or activated partial thromboplastin time (APTT) ≥ 1.5x ULN.
- CD19 B cells lower than the lower limit of the normal range

- 6) Used strong to medium CYP3A inducers within 3 weeks before treatment, or strong to medium CYP3A inhibitors within 1 week before treatment, or strong to medium CYP3A inducers or inhibitors may be used during treatment.

- 7) There are situations that other researchers think are not suitable to participate in this study.

Locations

Location

Status